A photo of Michelle Dickey.

Michelle P. Dickey, MS, APRN, CFNP, CPNP, CCRC

  • Nurse Practitioner
  • Field Service Instructor, Division of Infectious Diseases
  • Instructor, UC Department of Pediatrics


Services and Specialties

Infectious Diseases

Research Areas

Infectious Diseases


Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Lyke, KE; Atmar, RL; Islas, CD; Posavad, CM; Szydlo, D; Paul Chourdhury, R; Deming, ME; Eaton, A; Jackson, LA; Branche, AR; et al. Cell Reports Medicine. 2022; 3:100679.

Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial. Ortiz, JR; Spearman, PW; Goepfert, PA; Cross, K; Buddy Creech, C; Chen, WH; Parker, S; Overton, ET; Dickey, M; Logan, HL; et al. Vaccine. 2022; 40:3253-3262.

Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults. Frenck, RW; Conti, V; Ferruzzi, P; Ndiaye, AG W; Parker, S; McNeal, MM; Dickey, M; Granada, JP; Cilio, GL; De Ryck, I; et al. EClinicalMedicine. 2021; 39:101076.

Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults. Scaggs Huang, F; Bernstein, DI; Slobod, KS; Portner, A; Takimoto, T; Russell, CJ; Meagher, M; Jones, BG; Sealy, RE; Coleclough, C; et al. Human Vaccines and Immunotherapeutics. 2021; 17:554-559.

Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G. Clarkson, KA; Frenck, RW; Dickey, M; Suvarnapunya, AE; Chandrasekaran, L; Weerts, HP; Heaney, CD; McNeal, M; Detizio, K; Parker, S; et al. mSphere. 2020; 5:e00988-e00919.

Establishment of a Controlled Human Infection Model with a Lyophilized Strain of Shigella sonnei 53G. Frenck, RW; Dickey, M; Suvarnapunya, AE; Chandrasekaran, L; Kaminski, RW; Clarkson, KA; McNeal, M; Lynen, A; Parker, S; Hoeper, A; et al. mSphere. 2020; 5:e00416-e00420.

Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. Bernstein, DI; Guptill, J; Naficy, A; Nachbagauer, R; Berlanda-Scorza, F; Feser, J; Wilson, PC; Solorzano, A; Van der Wielen, M; Walter, EB; et al. Lancet Infectious Diseases. 2020; 20:80-91.

A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization. Bernstein, DI; Pasetti, MF; Brady, R; Buskirk, AD; Wahid, R; Dickey, M; Cohen, M; Baughman, H; El-Khorazaty, J; Maier, N; et al. Vaccine. 2019; 37:602-611.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

Overall Patient Rating